Sept. 7, 2023. New Stroke Treatment in Development at UTHSC.
June 20, 2023. Congratulations to Madison who won the inaugural Duane D. Miller Graduate Student Award in Drug Discovery! This new graduate student award was recently established by the UTHSC College of Pharmacy Drug Discovery Center (DDC) to honor the exceptional contributions of Dr. Duane D. Miller to the drug discovery and development at UTHSC over the past three decades. Only one graduate student is selected by the DDC faculty members each year to receive this highly competitive award along with a $250 check generously provided by Dr. Miller.
May 15, 2023. Jiange and Jerry’s research paper “Complementary roles of EP2 and EP4 receptors in malignant glioma” has been accepted for publication in British Journal of Pharmacology.
May 11, 2023. Congratulations to Dr. Madison Sluter for the successful public defense of her PhD dissertation “Development of Novel, Brain Permeable, mPGES-1 Inhibitors for Inflammatory Conditions”.
April 17, 2023. Madison’s review paper titled “The Inducible Prostaglandin E Synthase in Neuroinflammatory Disorders” has been accepted for publication in Experimental Biology and Medicine.
Mar. 23, 2023. Our collaborative work with Dr. Jianfeng Cai’s group at the University of South Florida “The discovery of cyclic γ-AApeptides as the promising ligands targeting EP2” is now published online in Bioorganic & Medicinal Chemistry Letters. It marks our 30th peer-reviewed publication since we moved to Memphis from Cincinnati in July 2018.
Mar. 13, 2023. Madison’s paper “Novel, Brain-Permeable, Cross-Species Benzothiazole Inhibitors of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Dampen Neuroinflammation In Vitro and In Vivo” has been formally accepted for publication as a full research article in ACS Pharmacology & Translational Science. This work is only possible through collaboration with Dr. Yang and Dr. Meibohm’s groups, highlighting the value of collaboration in drug discovery between labs of pharmacology, medicinal chemistry, pharmacokinetics and pharmaceutics. Congratulations to all authors who made this accomplishment possible!
Mar. 13, 2023. Our invited manuscript “Pharmacologically targeting transient receptor potential channels for seizures and epilepsy: Emerging preclinical evidence of druggability” has been accepted by Pharmacology & Therapeutics.
Mar. 7, 2023. Congratulations to Dr. Ruida Hou for the successful public defense of his PhD dissertation “Targeting prostaglandin E2 receptor EP2 for the treatment of high-risk neuroblastoma”.
Feb. 20, 2023. Ruida was selected to receive an AACR-Margaret Foti Foundation Scholar-in-Training Award in the amount of $1,200. AACR Scholar-in-Training Awards are competitive and are presented to those with high-quality abstracts and applications from a large candidate pool.
Feb. 7, 2023. Dr. Yu Chen received the 2023 Postdoctoral/Research Associate Award ($15,000) and a Travel Award ($500) from UTHSC Neuroscience Institute.
Jan. 25, 2023. Yu and Marwa’s review manuscript “Neuroinflammatory mediators in acquired epilepsy: An update” was accepted by Inflammation Research, the Official Journal of: The International Association of Inflammation Societies (IAIS) + The European Histamine Research Society (EHRS).
Jan. 19, 2023. Nelufar’s research paper “Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective” has been accepted for publication in Molecular Brain.
Jan. 18, 2023. Dr. Qianqian (Jerry) Li took the 3rd place in the platform presentation competition at UTHSC Annual Postdoc Research Showcase.
Jan. 17, 2023. Dr. Lexiao Li won the inaugural Outstanding Postdoctoral/Research Scholar Award, a new award established in 2022 to honor the scholarly achievements of a postdoctoral/research scholar affiliated with the University of Tennessee College of Pharmacy.
Jan. 17, 2023. Ruida received the 2022 University of Tennessee College of Pharmacy Outstanding Graduate Student Award for his exceptional scholarly achievements since he joined the lab in 2019.
Nov. 21, 2022. Nelufar, Madison, and Ying’s article entitled “Ganaxolone for management of seizures associated with CDKL5 deficiency disorder” was accepted by Trends in Pharmacological Sciences.
Nov. 1, 2022. Ruida’s review paper “Prostaglandin E2 in neuroblastoma: targeting synthesis or signaling?” was accepted by Biomedicine & Pharmacotherapy.
Oct. 25, 2022. Editorial on the Research Topic “Neuroinflammation in Acquired Epilepsy” was accepted by Frontiers in Cell and Developmental Biology.
Oct. 21, 2022. We were awarded a New Grant Support ($30,000) by the UTHSC Research Office for our research in cerebral ischemia.
Sept. 25, 2022. Nelufar was awarded a travel grant ($350) from American Association of Bangladeshi Pharmaceutical Scientists (AABPS).
July 14, 2022. Lexiao and Yu’s research paper “Ablation of Siglec-E augments brain inflammation and ischemic injury” has been accepted for publication in Journal of Neuroinflammation.
June 17, 2022. Our invited review paper “TRPC channels as emerging targets for seizure disorders” has been accepted by Trends in Pharmacological Sciences.
June 7, 2022. Graduate student Ruida Hou passed his Doctoral Qualifying Exam and advanced to a formal PhD candidate.
May 16, 2022. Ruida’s manuscript “Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma” was accepted for publication as a full research article in Cell Reports, a Cell Press journal.
April 21, 2022. A competition team formed by Madison and Lexiao won the first place in Tennessee Scipreneur Challenge 2022. Each received $500 prize money.
Jan. 31, 2022. Marwa, Sicheng, and Nelufar’s paper entitled “Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects” has been accepted for publication in Epilepsia, the Official Journal of the International League Against Epilepsy (ILAE).
Jan. 24, 2022. Lexiao was awarded a Neuroscience Postdoctoral/Research Associate Award ($15,000) and a travel award ($500) by the UTHSC Neuroscience Institute.
Jan. 15, 2022. Lexiao’s paper entitled “Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke” was accepted for publication in Neurotherapeutics, the Official Journal of the American Society for Experimental Neurotherapeutics (ASENT).
Dec. 21, 2021. Madison won the Outstanding PHAST Journal Club Presenter for the second time in a row.
Dec. 14, 2021. Graduate student Madison Sluter passed the Doctoral Qualifying Exam and officially became a PhD candidate.
Dec. 8, 2021. Technology described in our patent US10758516 “Methods and compositions for the treatment of gliomas” has been licensed to Nuvision Benefits.
Dec. 3, 2021. Postdoc fellow Dr. Lexiao Li won the 1st place among 14 presenters at 2021 UTHSC Annual Postdoc Research Showcase ($400 prize money) and secured one of the only three travel awards ($1,000).
Nov. 25, 2021. Research Topic Neuroinflammation in Acquired Epilepsy for Frontiers in Cell and Developmental Biology is now open for submissions.
Nov. 15, 2021. Congressman Cohen Announces Grant for Epilepsy Research.
Oct. 8, 2021. We received a New Grant Support ($30,000) from the UTHSC Research Office to study the blood-brain barrier integrity in acquired epilepsy.
May 12, 2021. Experimental status epilepticus, COX-2 and BDNF: Connecting the dots. Epilepsia Open.
April 21, 2021. PhD student Madison Sluter won the Outstanding Presenter Award in the Journal Club of the Department of Pharmacology, Addiction Science, and Toxicology.
Oct. 14, 2020. We received a New Grant Support ($20,000) from the UTHSC Research Office for our study on EP2 receptor in neuroblastoma.
April 28, 2020. PharmD student Davis Nguyen won the 2020 UTHSC College of Pharmacy Excellence in Scholarship and Research Award.
Feb. 9, 2019. Our research manuscript “Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury” was accepted for publication in Neuropharmacology.
Jan. 27, 2019. Our research paper “Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth” was accepted by British Journal of Pharmacology.
Dec. 20, 2018. We received a new R21 grant from the NIH/NINDS to study brain tumor-associated epilepsy.
July 1, 2018. Our lab was relocated to the University of Tennessee Health Science Center.